248 related articles for article (PubMed ID: 32557987)
1. An Open-Label Single-Arm Phase II Study of Treatment with Neoadjuvant S-1 Plus Cisplatin for Clinical Stage III Squamous Cell Carcinoma of the Esophagus.
Kanda M; Koike M; Iwata N; Shimizu D; Tanaka C; Hattori N; Hayashi M; Yamada S; Omae K; Nakayama G; Kodera Y
Oncologist; 2020 Nov; 25(11):e1650-e1654. PubMed ID: 32557987
[TBL] [Abstract][Full Text] [Related]
2. Comparison of neoadjuvant chemotherapy versus upfront surgery with or without chemotherapy for patients with clinical stage III esophageal squamous cell carcinoma.
Matsuda S; Tsubosa Y; Sato H; Takebayashi K; Kawamorita K; Mori K; Niihara M; Tsushima T; Yokota T; Onozawa Y; Yasui H; Takeuchi H; Kitagawa Y
Dis Esophagus; 2017 Feb; 30(2):1-8. PubMed ID: 26919154
[TBL] [Abstract][Full Text] [Related]
3. Neoadjuvant chemotherapy with S-1 plus cisplatin for esophageal squamous cell carcinoma.
Takahashi T; Kaneoka Y; Maeda A; Takayama Y; Seita K
Updates Surg; 2022 Apr; 74(2):675-683. PubMed ID: 34559400
[TBL] [Abstract][Full Text] [Related]
4. Neoadjuvant chemotherapy with docetaxel, nedaplatin, and fluorouracil for resectable esophageal cancer: A phase II study.
Ohnuma H; Sato Y; Hayasaka N; Matsuno T; Fujita C; Sato M; Osuga T; Hirakawa M; Miyanishi K; Sagawa T; Fujikawa K; Ohi M; Okagawa Y; Tsuji Y; Hirayama M; Ito T; Nobuoka T; Takemasa I; Kobune M; Kato J
Cancer Sci; 2018 Nov; 109(11):3554-3563. PubMed ID: 30137686
[TBL] [Abstract][Full Text] [Related]
5. Phase II trial of neoadjuvant chemotherapy with docetaxel, nedaplatin, and S1 for advanced esophageal squamous cell carcinoma.
Tanaka Y; Yoshida K; Tanahashi T; Okumura N; Matsuhashi N; Yamaguchi K
Cancer Sci; 2016 Jun; 107(6):764-72. PubMed ID: 27061001
[TBL] [Abstract][Full Text] [Related]
6. Prognostic Advantage of Docetaxel/Cisplatin/ 5-Fluorouracil Neoadjuvant Chemotherapy in Clinical Stage II/III Esophageal Squamous Cell Carcinoma due to Excellent Control of Preoperative Disease and Postoperative Lymph Node Recurrence.
Yamashita K; Hosoda K; Moriya H; Katada C; Sugawara M; Mieno H; Komori S; Katada N; Watanabe M
Oncology; 2017; 92(4):221-228. PubMed ID: 28110330
[TBL] [Abstract][Full Text] [Related]
7. Neoadjuvant chemoradiotherapy with docetaxel, cisplatin, and 5-fluorouracil (DCF-RT) for locally advanced esophageal squamous cell carcinoma.
Sasaki K; Uchikado Y; Omoto I; Arigami T; Osako Y; Noda M; Okumura H; Maemura K; Higashi R; Yoshiura T; Natsugoe S
Cancer Chemother Pharmacol; 2019 Mar; 83(3):581-587. PubMed ID: 30623230
[TBL] [Abstract][Full Text] [Related]
8. Analysis of SPARC and TUBB3 as predictors for prognosis in esophageal squamous cell carcinoma receiving nab-paclitaxel plus cisplatin neoadjuvant chemotherapy: a prospective study.
Gong L; Mao W; Chen Q; Jiang Y; Fan Y
Cancer Chemother Pharmacol; 2019 Apr; 83(4):639-647. PubMed ID: 30643929
[TBL] [Abstract][Full Text] [Related]
9. Neoadjuvant docetaxel, oxaliplatin plus S-1 for treating clinical stage III squamous cell carcinoma of the esophagus: Study protocol of an open-label phase II trial.
Kanda M; Shimizu D; Miyata K; Maeda O; Tanaka C; Inokawa Y; Hattori N; Hayashi M; Ando M; Kuwatsuka Y; Murotani K; Nakayama G; Koike M; Ando Y; Ebata T; Kodera Y
Contemp Clin Trials Commun; 2021 Dec; 24():100853. PubMed ID: 34820548
[TBL] [Abstract][Full Text] [Related]
10. Effect of Time to Minimally Invasive Esophagectomy After Neoadjuvant Chemotherapy for Esophageal Squamous Cell Carcinoma.
Loc NVV; Vuong NL; Trung LV; Trung TT
J Gastrointest Cancer; 2023 Dec; 54(4):1240-1251. PubMed ID: 36723785
[TBL] [Abstract][Full Text] [Related]
11. Long-term outcomes and safety of radical transmediastinal esophagectomy with preoperative docetaxel, cisplatin, and 5-fluorouracil combination chemotherapy for locally advanced squamous cell carcinoma of the thoracic esophagus.
Yamagata Y; Saito K; Hirano K; Oya M
World J Surg Oncol; 2020 Sep; 18(1):252. PubMed ID: 32962718
[TBL] [Abstract][Full Text] [Related]
12. Effects of Neoadjuvant 5-Fluorouracil and Cisplatin Therapy in Patients with Clinical Stage II/III Esophageal Squamous Cell Carcinoma.
Konishi H; Fujiwara H; Shiozaki A; Shoda K; Kosuga T; Kubota T; Okamoto K; Otsuji E
Anticancer Res; 2018 Feb; 38(2):1017-1023. PubMed ID: 29374735
[TBL] [Abstract][Full Text] [Related]
13. A retrospective clinical study of comparing paclitaxel plus S-1 versus paclitaxel plus cisplatin as the first-line treatment for patients with advanced esophageal squamous cell carcinoma.
Wang HY; Yao ZH; Tang H; Zhao Y; Jin SL; Zhou WP; Yao SN; Yang SJ; Liu YY; Luo SX
Oncotarget; 2017 Jan; 8(5):7540-7547. PubMed ID: 27902478
[TBL] [Abstract][Full Text] [Related]
14. Prognostic Factors in Patients Receiving Neoadjuvant 5-Fluorouracil plus Cisplatin for Advanced Esophageal Cancer (JCOG9907).
Yokota T; Ando N; Igaki H; Shinoda M; Kato K; Mizusawa J; Katayama H; Nakamura K; Fukuda H; Kitagawa Y
Oncology; 2015; 89(3):143-51. PubMed ID: 25895447
[TBL] [Abstract][Full Text] [Related]
15. Phase II feasibility study of preoperative concurrent chemoradiotherapy with cisplatin plus 5-fluorouracil and elective lymph node irradiation for clinical stage II/III esophageal squamous cell carcinoma.
Hashimoto J; Kato K; Ito Y; Kojima T; Akimoto T; Daiko H; Hamamoto Y; Matsushita H; Katano S; Hara H; Tanaka Y; Saito Y; Nagashima K; Igaki H
Int J Clin Oncol; 2019 Jan; 24(1):60-67. PubMed ID: 30109544
[TBL] [Abstract][Full Text] [Related]
16. The prognostic significance of the positive circumferential resection margin in pathologic T3 squamous cell carcinoma of the esophagus with or without neoadjuvant chemotherapy.
Okada N; Fujii S; Fujita T; Kanamori J; Kojima T; Hayashi R; Daiko H
Surgery; 2016 Feb; 159(2):441-50. PubMed ID: 26391150
[TBL] [Abstract][Full Text] [Related]
17. Neoadjuvant Chemotherapy with Docetaxel, Cisplatin and S-1 for Resectable Advanced Esophageal Cancer.
Hayata K; Ojima T; Nakamori M; Nakamura M; Katsuda M; Kitadani J; Takeuchi A; Tabata H; Maruoka S; Yamaue H
Anticancer Res; 2018 Sep; 38(9):5267-5273. PubMed ID: 30194177
[TBL] [Abstract][Full Text] [Related]
18. Neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for locally advanced oesophageal squamous cell carcinoma: a single-Centre, open-label, randomized, controlled, clinical trial (HCHTOG1903).
Sun HB; Xing WQ; Liu XB; Zheng Y; Yang SJ; Wang ZF; Liu SL; Ba YF; Zhang RX; Liu BX; Fan CC; Chen PN; Liang GH; Yu YK; Liu Q; Wang HR; Li HM; Li ZX;
BMC Cancer; 2020 Apr; 20(1):303. PubMed ID: 32293362
[TBL] [Abstract][Full Text] [Related]
19. A Pilot Trial of S-1 and Paclitaxel in Unresectable or Postoperative Recurrent Esophageal Squamous Cell Carcinoma Pretreated by Fluorouracil, Cisplatin, and Docetaxel Chemotherapy.
Nakajima Y; Kawada K; Tokairin Y; Hoshino A; Okada T; Kawano T
Dig Surg; 2018; 35(2):131-137. PubMed ID: 28554183
[TBL] [Abstract][Full Text] [Related]
20. Neoadjuvant versus adjuvant chemoradiation for stage II-III esophageal squamous cell carcinoma: a single institution experience.
Chen Y; Hao D; Wu X; Xing W; Yang Y; He C; Wang W; Liu J; Wang J
Dis Esophagus; 2017 Jul; 30(7):1-7. PubMed ID: 28475725
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
